• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Xanthine Oxidase Inhibitor Withdrawal Syndrome? Comment on the Article by Choi et al.

作者信息

Johnson Todd A, Kamatani Naoyuki, Kuwabara Masanari

机构信息

StaGen Co.

Toranomon Hospital, Tokyo, Japan.

出版信息

Arthritis Rheumatol. 2019 Nov;71(11):1966-1967. doi: 10.1002/art.41066. Epub 2019 Sep 20.

DOI:10.1002/art.41066
PMID:31379099
Abstract
摘要

相似文献

1
Xanthine Oxidase Inhibitor Withdrawal Syndrome? Comment on the Article by Choi et al.黄嘌呤氧化酶抑制剂戒断综合征？对崔等人文章的评论
Arthritis Rheumatol. 2019 Nov;71(11):1966-1967. doi: 10.1002/art.41066. Epub 2019 Sep 20.
2
Excess Deaths Upon Cessation of Xanthine Oxidase Inhibitor Treatment-Data From the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial: Comment on the Article by Choi et al.黄嘌呤氧化酶抑制剂治疗停止后的额外死亡——来自非布司他和别嘌醇对痛风合并心血管疾病患者心血管安全性试验的数据：对Choi等人文章的评论
Arthritis Rheumatol. 2019 Aug;71(8):1391-1392. doi: 10.1002/art.40914. Epub 2019 Jun 4.
3
Limitations in Assessing Cardiovascular Risk of Febuxostat in Patients With Gout and Cardiovascular Morbidities: Comment on the Article by Choi et al.评估非布司他在痛风合并心血管疾病患者中心血管风险的局限性：对Choi等人文章的评论
Arthritis Rheumatol. 2019 Jun;71(6):1023-1024. doi: 10.1002/art.40838. Epub 2019 Apr 12.
4
Fresh Perspectives on the CARES Trial and the Use of Febuxostat in an Asian Population: Comment on the Article by Choi et al.对CARES试验及非布司他在亚洲人群中应用的新观点：对Choi等人文章的评论
Arthritis Rheumatol. 2019 Mar;71(3):479-481. doi: 10.1002/art.40741.
5
Febuxostat Does Not Increase All-Cause Mortality and Cardiovascular Mortality Compared With Placebo: Comment on the Article by Choi et al.与安慰剂相比，非布司他不会增加全因死亡率和心血管死亡率：对Choi等人文章的评论
Arthritis Rheumatol. 2019 Mar;71(3):479. doi: 10.1002/art.40744.
6
Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.非布司他：一种选择性黄嘌呤氧化酶/黄嘌呤脱氢酶抑制剂，用于治疗成人痛风患者的高尿酸血症。
Clin Ther. 2009 Nov;31(11):2503-18. doi: 10.1016/j.clinthera.2009.11.033.
7
Febuxostat for the treatment of gout.非布司他用于痛风的治疗。
Expert Opin Pharmacother. 2015 Feb;16(3):395-8. doi: 10.1517/14656566.2015.985588. Epub 2015 Jan 5.
8
An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.一种别嘌醇对照、随机、双盲、双模拟、平行分组、比较研究，评估黄嘌呤氧化酶非嘌呤选择性抑制剂非布司他（TMX-67）在包括痛风患者在内的高尿酸血症患者中的疗效：3 期临床研究。
J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S13-8. doi: 10.1097/RHU.0b013e31821d36cc.
9
An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.一项别嘌醇对照、多中心、随机、开放标签、平行分组、比较研究，评估黄嘌呤氧化酶非嘌呤选择性抑制剂非布司他（TMX-67）在日本高尿酸血症患者（包括痛风患者）中的疗效：Ⅱ期探索性临床研究。
J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S44-9. doi: 10.1097/RHU.0b013e31821d352f.
10
Urate-lowering therapy for gout: focus on febuxostat.降尿酸治疗痛风：聚焦非布司他。
Pharmacotherapy. 2010 Jun;30(6):594-608. doi: 10.1592/phco.30.6.594.

引用本文的文献

1
Current updates and future perspectives in uric acid research, 2024.2024年尿酸研究的最新进展与未来展望
Hypertens Res. 2025 Feb;48(2):867-873. doi: 10.1038/s41440-024-02031-9. Epub 2024 Dec 3.
2
Association between Body Mass Index and Serum Uric Acid: mediation analysis involving liver enzymes indicators.体重指数与血清尿酸的关系：涉及肝酶指标的中介分析。
BMC Public Health. 2024 Oct 30;24(1):3007. doi: 10.1186/s12889-024-20457-1.
3
Xanthine oxidase inhibitors treatment or discontinuation effects on mortality: evidence of xanthine oxidase inhibitors withdrawal syndrome.
黄嘌呤氧化酶抑制剂治疗或停药对死亡率的影响：黄嘌呤氧化酶抑制剂撤药综合征的证据。
Front Pharmacol. 2024 Jan 8;14:1289386. doi: 10.3389/fphar.2023.1289386. eCollection 2023.
4
Update in uric acid, hypertension, and cardiovascular diseases.尿酸、高血压和心血管疾病的最新进展。
Hypertens Res. 2023 Jul;46(7):1714-1726. doi: 10.1038/s41440-023-01273-3. Epub 2023 Apr 18.
5
Cardiovascular and kidney outcomes of uric acid-lowering therapy in patients with different kidney functions: study protocol for a systematic review, pairwise and network meta-analysis.不同肾功能患者降尿酸治疗的心血管和肾脏结局：系统评价、成对和网络荟萃分析的研究方案。
BMJ Open. 2023 Feb 8;13(2):e059096. doi: 10.1136/bmjopen-2021-059096.
6
Association of Mutations Identified in Xanthinuria with the Function and Inhibition Mechanism of Xanthine Oxidoreductase.黄嘌呤尿症中鉴定出的突变与黄嘌呤氧化还原酶的功能及抑制机制的关联
Biomedicines. 2021 Nov 20;9(11):1723. doi: 10.3390/biomedicines9111723.
7
Hyperuricemia and chronic kidney disease: to treat or not to treat.高尿酸血症与慢性肾脏病：治疗还是不治疗。
J Bras Nefrol. 2021 Oct-Dec;43(4):572-579. doi: 10.1590/2175-8239-JBN-2020-U002.
8
Hyperuricemia in Kidney Disease: A Major Risk Factor for Cardiovascular Events, Vascular Calcification, and Renal Damage.高尿酸血症与肾脏病：心血管事件、血管钙化和肾脏损害的重要危险因素。
Semin Nephrol. 2020 Nov;40(6):574-585. doi: 10.1016/j.semnephrol.2020.12.004.
9
Uric Acid and Hypertension: An Update With Recommendations.尿酸与高血压：更新与建议。
Am J Hypertens. 2020 Jul 18;33(7):583-594. doi: 10.1093/ajh/hpaa044.